Pivekimab, known as IBAT®, constitutes one unique recombinant targeted protein developed to directly target while inhibit IL-6 cytokine, the key inflammatory mediator implicated with the pathogenic mechanisms driving inflammatory illnesses. This medicinal compound has been produced by cell geneti